Clinical Trials Browser

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

INDIGO

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

EPIC

Neo-Kan

BIB 01

EMPIRE

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

TUXEDO-5

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

NEGOTIATE

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

APPEAL

AERESA

NAJSCR

AMBER

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

BOUNCE

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Re-Induce 2

SCION

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

LURBIMUNE

STRIDER

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Non-Viral TCR Gene Therapy

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

XQonc-007

INTRUSION

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

NSCLC

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

REFIT-MSS

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery